Country: European Union
Language: English
Source: EMA (European Medicines Agency)
Vosoritide
BioMarin International Limited
M05BX
vosoritide
Drugs for treatment of bone diseases
Achondroplasia
Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
Revision: 4
Authorised
2021-08-26
36 B. PACKAGE LEAFLET 37 PACKAGE LEAFLET: INFORMATION FOR THE USER VOXZOGO 0.4 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VOXZOGO 0.56 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION VOXZOGO 1.2 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION vosoritide This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you or your child may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you or your child has any further questions, ask your doctor. - This medicine has been prescribed for you or your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you or your child gets any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Voxzogo is and what it is used for 2. What you need to know before you use Voxzogo 3. How to use Voxzogo 4. Possible side effects 5. How to store Voxzogo 6. Contents of the pack and other information 1. WHAT VOXZOGO IS AND WHAT IT IS USED FOR WHAT VOXZOGO IS Voxzogo contains the active substance vosoritide. It is similar to a protein in the body called C type natriuretic peptide (CNP). Vosoritide is made by recombinant technology involving bacteria that have been modified to include the gene for producing the protein. WHAT VOXZOGO IS USED FOR This medicine is used for the treatment of achondroplasia in patients 4 months of age and older whose bones are still growing. Achondroplasia is a genetic condition that affects growth of almost all bones in the body including the skull, spine, arms and legs resulting in very short stature with a characteristic appearance _._ The product is indicated only in achondroplasia which is caused by mutations i Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Voxzogo 0.4 mg powder and solvent for solution for injection Voxzogo 0.56 mg powder and solvent for solution for injection Voxzogo 1.2 mg powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Voxzogo 0.4 mg powder and solvent for solution for injection Each vial of powder contains 0.4 mg of vosoritide*. After reconstitution, each vial contains 0.4 mg vosoritide in 0.5 mL of solution, corresponding to a concentration of 0.8 mg/mL. Voxzogo 0.56 mg powder and solvent for solution for injection Each vial of powder contains 0.56 mg of vosoritide*. After reconstitution, each vial contains 0.56 mg vosoritide in 0.7 mL of solution, corresponding to a concentration of 0.8 mg/mL. Voxzogo 1.2 mg powder and solvent for solution for injection Each vial of powder contains 1.2 mg of vosoritide*. After reconstitution, each vial contains 1.2 mg vosoritide in 0.6 mL of solution, corresponding to a concentration of 2 mg/mL. *produced in _Escherichia coli_ cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection. The powder is white to yellow and the solvent is clear and colourless. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with vosoritide should be initiated and directed by a physician appropriately qualified in the management of growth disorders or skeletal dysplasias. 3 Posology Voxzogo is given as a Read the complete document